Table 2 Post-induction and post-transplant responsesa.

From: Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients

 

Post-induction response

Post-transplant response

 

D-RVD, N = 325 (%)

RVD, N = 977 (%)

p-value

D-RVD, N = 271 (%)

RVD, N = 814 (%)

p-value

Stringent complete response (sCR)

41 (12.6)

39 (4)

 

87 (32.1)

258 (31.7)

 

Complete response (CR)

29 (8.9)

312 (31.9)

 

29 (10.7)

318 (39.1)

 

Very good partial response (VGPR)

211 (64.9)

309 (31.6)

 

143 (52.8)

156 (19.2)

 

≥VGPR

281 (86.5)

660 (67.6)

<0.001

259 (95.6)

732 (89.9)

0.002

Partial response (PR)

43 (13.2)

289 (29.6)

 

10 (3.7)

71 (8.7)

 

≥PR

325 (99.6)

949 (97.1)

 

269 (99.2)

803 (98.6)

 

Stable disease (SD)

1 (0.3)

17 (1.7)

 

0 (0)

2 (0.2)

 

Progressive disease (PD)

0 (0)

11 (1.1)

 

2 (0.7%)

9 (1.1)

 
  1. a325 evaluable for post-induction responses and 271 for post-transplant responses in DRVd arm; 977 evaluable for post-induction response and 814 for post-transplant responses in the RVd arm.
Back to article page